Lineage Cell Therapeutics (LCTX) Payables (2010 - 2026)

Lineage Cell Therapeutics' Payables history runs 17 years deep, the most recent figure standing at $5.6 million for Q1 2026.

• On a quarterly basis, Payables rose 179.05% year-over-year to $5.6 million in Q1 2026; TTM through Mar 2026 was $5.6 million, a 179.05% increase from a year earlier, with the FY2025 full-year figure at $2.3 million, down 56.94% from the prior year.
• Payables grew to $5.6 million in Q1 2026 per LCTX's latest filing, from $2.3 million in the prior quarter.
• Across five years, Payables topped out at $9.8 million in Q3 2022 and bottomed at $1.5 million in Q2 2025.
• The 5-year median for Payables is $5.3 million (2023), against an average of $5.4 million.
• Across the five-year window, Payables soared 220.24% in 2022 and slumped 70.17% in 2025, its largest moves.
• Year by year, Payables stood at $8.6 million in 2022, then fell by 27.16% to $6.3 million in 2023, then decreased by 13.29% to $5.4 million in 2024, then tumbled by 56.94% to $2.3 million in 2025, then soared by 137.8% to $5.6 million in 2026.
• Per Business Quant, the three latest LCTX Payables figures stand at $5.6 million (Q1 2026), $2.3 million (Q4 2025), and $4.6 million (Q3 2025).